December 03, 2025
More than 1 in 10 people in Canada experience major depressive disorder (MDD) at some point in their lives. Although it can be treated in many ways, antidepressants are a common, easily accessible option.
However, finding the right medication can be a long process. It may involve trying different types and doses, dealing with side effects, and understanding if they can provide relief for the right symptoms. All this requires extensive time and resources.
Pharmacogenomic testing (PGx) can assist in the process. Because our genetics contributes to our bodies’ response to medication, PGx tests can provide information to guide antidepressant selection and dosing.
Policymakers in British Columbia are currently considering if PGx testing to improve antidepressant prescriptions should be offered through the health system. This can make a huge difference to people who need access to depression care, as well as healthcare workers.
A Genome BC project co-led by Indigenous and non-Indigenous researchers — Dr. J9 Austin, Dr. Brittany Bingham and Dr. Stirling Bryan from the University of British Columbia (UBC) — will involve discussions on PGx testing with Indigenous leaders in research, healthcare and government, as well as community members. The project’s overarching goal is to lay the groundwork for genomic and mental health research to take root and flourish for Indigenous Peoples in BC.
With the absence of research that highlights Indigenous Peoples’ perspectives on PGx testing in Canada, this work is filling a crucial information gap in this space. Ultimately, the team wants to ensure that policymaking takes cultural safety into account.
“As we move towards conversations about whether and how to roll this out, it is critically important ensure that Indigenous communities are centred in discussions, such that the potential for harm is minimized and that equitable access is prioritized for anyone who would want to access this option,” reflects Dr. Austin.
Dr. Austin, Dr. Bryan and their team have been evaluating the potential health benefits, cost-savings, and implementation approaches of PGx testing for major depression over several years. This project is a partnership with Dr. Bingham, a member of the shíshálh nation, a leader in Indigenous community-driven health and policy research, and Founder and Lead of the Indigenous Health Equity Lab at UBC and the Women’s Health Research Institute.
“We chose the name Strengthening Trust through Equitable Methods (STEM) to reflect both the scientific foundation, and the goal of understanding and uplifting Indigenous perspectives in this work. We aim to amplify Indigenous voices, ensuring that they are at the forefront of implementation efforts for PGx testing for MDD,” says Dr. Bingham.
Read more about the previous Genome BC funded project on PGx.
-30-
Contact: Genie Tay, Communications Specialist
